Phase-II Study of Docetaxel, Estramustine Phosphate, and Carboplatin in Patients with Hormone-Refractory Prostate Cancer

European Urology

Volumn 51, Issue 5, 2007, Pages 1252-1258

  Kikuno, Nobuyuki ^a   Urakami, Shinji ^a   Nakamura, Shigeru ^a   Hiraoka, Takeo ^a   Hyuga, Taijyu ^a   Arichi, Naoko ^a   Wake, Kouji ^a   Sumura, Masahiro ^a   Yoneda, Tatsuaki ^a   Kishi, Hirofumi ^a   Shigeno, Kazushi ^a   Shiina, Hiroaki ^a   Igawa, Mikio ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Carboplatin; Docetaxel; Estramustine phosphate; Hormone refractory prostate cancer

Indexed keywords

ANTIANDROGEN; CARBOPLATIN; CORTICOSTEROID; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; FLUOROURACIL; GONADORELIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HORMONE REFRACTORY PROSTATE CANCER; HORMONE RESISTANCE; HUMAN; LEUKOPENIA; LIVER FUNCTION; LUNG INFILTRATE; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 33947249446     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.12.030     Document Type: Article

References (30)

1. Petrylak D.P., Tangen C.M., Maha H.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
2. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
3. Lavelle F., Bissery M.C., Combeau C., et al. Preclinical evaluation of docetaxel (Taxotere). SeminOncol 22 Suppl 4 (1995) 3-16
4. Haldar S., Basu A., and Croce C. Bcl-2 is the guardian of microtubule integrity. Cancer Res 57 (1997) 229-233
5. Speicher L., Liang N., Barone L., et al. Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Molecular Pharmacol 46 (1994) 8866-8872
6. Kreis W., Budman D., and Calabro A. Unique synergism or antagonism of combination of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 79 (1997) 196-202
7. Hartley-Asp B., and Gunnarson P. Growth and cell survival following treatment with estramustine, nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU-145). J Urol 17 (1982) 818-822
8. Hartley-Asp B. Estramustine-induced mitotic arrest in tow human prostatic carcinoma cell line DU-145 and PC-3. Prostate 5 (1984) 93-100
9. Speicher L.A., Barone L., and Tew K.D. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52 (1992) 4433-4440
10. Hudes G.R., Nathan F., Khater C., et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15 (1997) 3156-3163
11. Kelly W.K., Curley T., Slovin S., et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19 (2001) 44-53
12. Wagstaff A.J., Ward A., Benfield P., et al. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37 (1989) 162-190
13. Canobbio L., Guarneri D., Miglietta L., et al. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 29A (1993) 2094-2096
14. Jungi W.F., Bernhard J., Hurny C., et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for clinical cancer research (SAKK). Support Care Cancer 5 (1998) 462-468
15. Engblom P., Rantanen V., Kulmala J., et al. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro. Cancer 86 (1999) 2066-2073
16. Oh W.K., Halabi S., Kelly W.K., et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 98 (2003) 2592-2598
17. Oh W.K., Hagmann E., Manola J., et al. A phase I study of estramustine, weekly docetaxel, and carboplatin in patients with hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 284-289
18. Urakami S., Yoshino T., Kikuno N., et al. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. Urology 65 (2005) 543-548
19. Urakami S., Igawa M., Kikuno N., et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 168 (2002) 2444-2450
20. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461-3467
21. Culine S., and Droz J.P. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?. Ann Oncol 11 (2000) 1523-1528
22. Smaletz O., Scher H.I., Small E.J., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002) 3972-3982
23. Halabi Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232-1237
24. Svatek R., Karakiewicz P.I., Shulman M., Karam J., Perrotte P., and Benaim E. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. Eur Urol 49 (2006) 666-674
25. Oh W.K., and Kantoff P.W. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160 (1998) 1220-1229
26. Gravis G., Bladou F., Salem N., et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 98 (2003) 1627-1634
27. Kantoff P. Recent progress in management of advanced prostate cancer. Oncology 19 (2005) 631-636
28. Clarke N.W. Management of the spectrum of hormone refractory prostate cancer. Eur Urol 50 (2006) 428-439
29. Calabrò F., and Sternberg C.N. Current indications for chemotherapy in prostate cancer patients. Eur Urol 51 (2007) 17-26
30. di Sant'Agnese P.A. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 12 (2001) S135-S140